Publications by authors named "L Castera"
Background And Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe subtype, metabolic dysfunction-associated steatohepatitis (MASH), are highly prevalent and strongly associated with obesity and type 2 diabetes (T2D). This study sought to identify challenges to the diagnosis, treatment and management of people living with MASLD and MASH and understand the key barriers to adopting relevant clinical guidelines.
Methods: A real-world, cross-sectional study (BARRIERS-MASLD) consisting of a quantitative survey and qualitative interviews of physicians in France, Germany, Italy, Spain and the United Kingdom was conducted from March to September 2023.
Article Synopsis
- * The study collected and analyzed 1,600 posts from various countries, revealing that the most common topics included patients' journeys (92%), comorbidities (38%), and their interactions with healthcare professionals (26%).
- * Major findings indicated that unhealthy diets and obesity are significant risk factors, with fatigue and abdominal pain being prevalent symptoms; meanwhile, the disease has a considerable negative impact on patients' quality of life, especially for those with comorbidities and more severe conditions.
Article Synopsis
- ACBP/DBI is a protein linked to metabolic-associated steatohepatitis and liver fibrosis, showing higher levels in affected patients, correlating strongly with NAFLD and FIB4 scores, regardless of age or body mass index.
- A study used a monoclonal antibody to neutralize ACBP/DBI in various mouse models of liver disease, resulting in reduced signs of liver damage and halting disease progression.
- The results suggest ACBP/DBI plays a causal role in liver conditions and could be a potential therapeutic target for treating liver diseases.
Background: Liver disease assessment is a key aspect of chronic hepatitis C virus (HCV) infection pre-treatment evaluation but guidelines differ on the optimal testing modality given trade-offs in availability and accuracy. We compared clinical outcomes and cost-effectiveness of common fibrosis staging strategies.
Methods: We simulated adults with chronic HCV receiving care at US health centers through a lifetime microsimulation across five strategies: (1) no staging or treatment (comparator), (2) indirect serum biomarker testing (Fibrosis-4 index [FIB-4]) only, (3) transient elastography (TE) only, (4) staged approach: FIB-4 for all, TE only for intermediate FIB-4 scores (1.
Background: Patients with advanced chronic liver disease (ACLD) are at high risk of developing hepatocellular carcinoma (HCC). Therefore, biannual surveillance is recommended. This large-scale multicenter study aimed to stratify the risk of HCC development in ACLD.
View Article and Find Full Text PDF